inability or unwillingness of participant or legally acceptable representative to give written informed consent any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine allergy to any study vaccine or any active substance in a study vaccine bleeding disorder or history of significant bleeding following im injections or venipuncture continuous use of anticoagulants a history of anaphylaxis to a previous vaccine pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine mosaic-1: history of laboratory-confirmed covid-19 disease prior to enrolment by participant report administration of a live virus vaccine within 4 weeks prior to study vaccine receipt.

inability or unwillingness of participant or legally acceptable representative to give written informed consent any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine allergy to any study vaccine or any active substance in a study vaccine bleeding disorder or history of significant bleeding following im injections or venipuncture continuous use of anticoagulants a history of anaphylaxis to a previous vaccine pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine mosaic-1: history of laboratory-confirmed covid-19 disease prior to enrolment by participant report administration of a live virus vaccine within 4 weeks prior to study vaccine receipt.

inability or unwillingness of participant or legally acceptable representative to give written informed consent any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine allergy to any study vaccine or any active substance in a study vaccine bleeding disorder or history of significant bleeding following im injections or venipuncture continuous use of anticoagulants a history of anaphylaxis to a previous vaccine pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine history of laboratory-confirmed covid-19 disease prior to enrolment by participant report

inability or unwillingness of participant or legally acceptable representative to give written informed consent any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine allergy to any study vaccine or any active substance in a study vaccine bleeding disorder or history of significant bleeding following im injections or venipuncture continuous use of anticoagulants a history of anaphylaxis to a previous vaccine pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine history of laboratory-confirmed covid-19 disease prior to enrolment by participant report

1. inability or unwillingness of participant or legally acceptable representative to give written informed consent 2. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids 3. current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) 4. administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine 5. allergy to any study vaccine or any active substance in a study vaccine 6. bleeding disorder or history of significant bleeding following im injections or venipuncture 7. continuous use of anticoagulants 8. a history of anaphylaxis to a previous vaccine 9. pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine 10. history of laboratory-confirmed covid-19 disease prior to enrolment by participant report

1. inability or unwillingness of participant or legally acceptable representative to give written informed consent 2. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids 3. current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) 4. administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine 5. allergy to any study vaccine or any active substance in a study vaccine 6. bleeding disorder or history of significant bleeding following im injections or venipuncture 7. continuous use of anticoagulants 8. a history of anaphylaxis to a previous vaccine 9. pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine 10. history of laboratory-confirmed covid-19 disease prior to enrolment by participant report

1. inability or unwillingness of participant or legally acceptable representative to give written informed consent 2. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids 3. current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) 4. administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine 5. allergy to any study vaccine or any active substance in a study vaccine 6. bleeding disorder or history of significant bleeding following im injections or venipuncture 7. continuous use of anticoagulants 8. a history of anaphylaxis to a previous vaccine 9. pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine 10. history of laboratory-confirmed covid-19 disease prior to enrolment by participant report 11. history of major venous and/or arterial thrombosis with thrombocytopenia following vaccination with astrazeneca covid-19 vaccine/covishield 12. history of previous cvst with thrombocytopenia or hit at any time

1. inability or unwillingness of participant or legally acceptable representative to give written informed consent 2. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids 3. current diagnosis or treatment for cancer (except basal cell carcinoma of the skin) 4. administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine 5. allergy to any study vaccine or any active substance in a study vaccine 6. bleeding disorder or history of significant bleeding following im injections or venipuncture 7. continuous use of anticoagulants 8. a history of anaphylaxis to a previous vaccine 9. pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine 10. history of laboratory-confirmed covid-19 disease prior to enrolment by participant report 11. history of major venous and/or arterial thrombosis with thrombocytopenia following vaccination with astrazeneca covid-19 vaccine/covishield 12. history of previous cvst with thrombocytopenia or hit at any time